<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862015</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-IMGPB-2016-03</org_study_id>
    <nct_id>NCT02862015</nct_id>
  </id_info>
  <brief_title>Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients</brief_title>
  <acronym>Oncothermia</acronym>
  <official_title>A Multicenter, Prospective, Randomized Clinical Trial of the Clinical Effectiveness of Oncothermia Combined With Standard Chemotherapy in Metastatic Pancreatic Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospicare Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with pancreatic cancer often suffer from pain. Because of such a pain, their quality
      of life have seriously deteriorated. There have been a few studies that showed an effect for
      pain control by hyperthermia (heating the patient's body). However, there are several
      limitations in conventional hyperthermia.

      In a previous pilot study (NCT02150135), we found the improvement of quality of life,
      function, and symptom.

      From this background, the investigators tried to show the effect of &quot;Oncothermia&quot; with
      conventional chemotherapy for pain control, increasing quality of life, and anti-tumor
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30 score change</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of opioid use amount</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of pain score (VAS score)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer, Pancreas</condition>
  <arm_group>
    <arm_group_label>Oncothermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with oncothermia treatment and palliative chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with palliative chemotherapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oncothermia</intervention_name>
    <description>Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.</description>
    <arm_group_label>Oncothermia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX or Gemcitabine based chemotherapy</intervention_name>
    <description>As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.</description>
    <arm_group_label>Oncothermia</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologically confirmed pancreatic adenocarcinoma

          -  Patients with radiologically identified metastasis (CT or MRI)

          -  Patients with no history of previous chemotherapy

          -  Patients with ECOG score 0-2

        Exclusion Criteria:

          -  Patients who have an experience of hyperthermia treatment

          -  Patients who have a difficulty of sensing heat

          -  Patients who have a skin graft or breast reconstruction surgery

          -  Patients who have a cardiac pacemaker or an implanted metal

          -  Pregnant or breast feeding women

          -  Patients with uncontrolled infection, diabetes, hypertension, ischemic heart disease,
             myocardial infarct within 6 months

          -  Patients who were treated with unproved drugs within 30 days

          -  Patients who have a serious disease which can affect the person's safety

          -  Patients who do not consent to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Hyeok Hwang, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-Hyeok Hwang, MD PhD</last_name>
    <phone>+82-31-787-7017</phone>
    <email>woltoong@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaihwan Kim, MD</last_name>
    <phone>+82-31-787-7075</phone>
    <email>drjaihwan@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Hyeok Hwang, MD PhD</last_name>
      <phone>+82-31-787-7017</phone>
    </contact>
    <investigator>
      <last_name>Jin-Hyeok Hwang, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaihwan Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2016</study_first_submitted>
  <study_first_submitted_qc>August 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>October 29, 2017</last_update_submitted>
  <last_update_submitted_qc>October 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

